Specifically, frequencies of CD133+ lymphoid-primed multipotent progenitors (LMPP) and CD133+ granulocyte–monocyte progenitors (GMP) were significantly higher in CML-BP compared to de novo BCR::ABL1+AML (Fig. 2F, G). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.